| Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. IF Tannock, D Osoba, MR Stockler, DS Ernst, AJ Neville, MJ Moore, ... Journal of clinical oncology 14 (6), 1756-1764, 1996 | 1877 | 1996 |
| Bisphosphonates for breast cancer N Pavlakis, RL Schmidt, MR Stockler Cochrane Database of Systematic Reviews, 2005 | 588 | 2005 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... Journal of clinical oncology 28 (19), 3191-3198, 2010 | 429 | 2010 |
| Single agent versus combination chemotherapy for metastatic breast cancer S Carrick, S Parker, CE Thornton, D Ghersi, J Simes, N Wilcken Cochrane Database of Systematic Reviews, 2009 | 368 | 2009 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 304 | 2019 |
| Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials YY Soon, MR Stockler, LM Askie, MJ Boyer Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2009 | 239 | 2009 |
| Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer M Stockler, NRC Wilcken, D Ghersi, RJ Simes Cancer treatment reviews 26 (3), 151-168, 2000 | 234 | 2000 |
| Bisphosphonates and other bone agents for breast cancer MHF Wong, MR Stockler, N Pavlakis Cochrane database of systematic reviews, 2012 | 230 | 2012 |
| Third consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ... Annals of oncology 20 (11), 1771-1785, 2009 | 216 | 2009 |
| Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials A Gennari, M Stockler, M Puntoni, M Sormani, O Nanni, D Amadori, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2011 | 203 | 2011 |
| Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer P Glare, G Pereira, LJ Kristjanson, M Stockler, M Tattersall Supportive Care in Cancer 12 (6), 432-440, 2004 | 166 | 2004 |
| Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, ... Journal of Clinical Oncology 32 (13), 1309, 2014 | 165 | 2014 |
| Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, J Dennis, ... JNCI: Journal of the National Cancer Institute 109 (7), 2017 | 154 | 2017 |
| Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial MR Stockler, R O'Connell, AK Nowak, D Goldstein, J Turner, ... The lancet oncology 8 (7), 603-612, 2007 | 150 | 2007 |
| Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer MR Stockler, VJ Harvey, PA Francis, MJ Byrne, SP Ackland, B Fitzharris, ... J Clin Oncol 29 (34), 4498-4504, 2011 | 147 | 2011 |
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 … D Stark, M Nankivell, E Pujade-Lauraine, G Kristensen, L Elit, M Stockler, ... The lancet oncology 14 (3), 236-243, 2013 | 146 | 2013 |
| Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 … GM Duchesne, HH Woo, JK Bassett, SJ Bowe, C D'Este, M Frydenberg, ... The Lancet Oncology 17 (6), 727-737, 2016 | 141 | 2016 |
| Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review CA Hauser, MR Stockler, MHN Tattersall Supportive Care in Cancer 14 (10), 999-1011, 2006 | 137 | 2006 |
| Evidence-based medicine: useful tools for decision making. JC Craig, LM Irwig, MR Stockler The Medical Journal of Australia 174 (5), 248-253, 2001 | 137 | 2001 |
| Second consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, ... Annals of oncology 18 (2), 215-225, 2007 | 136 | 2007 |
Val GebskiNHMRC Clinical TRials Centre, University of SydneyVerified email at ctc.usyd.edu.au
